The Gene-Editing Conversation
By Matthew C. Nisbet,
American Scientist
| 01. 01. 2018
Public dialogue about the new technology will require major investments from scientists, journalists, and philanthropists.
In 2014 biochemist Jennifer Doudna of the University of California at Berkeley awoke from a nightmare that would shift the focus of her world-class scientific career. Two years earlier, with her colleague Emmanuelle Charpentier, now director of the Max Planck Unit for the Science of Pathogens in Berlin, Doudna had achieved one of the most stunning breakthroughs in the history of biology, becoming the first to use a process called CRISPR-Cas9 to alter the genetic makeup of living organisms. Their “gene-editing” tool would allow scientists to efficiently insert or delete specific bits of DNA with unprecedented precision.
But as applications related to modifying human genes were soon reported in the scientific literature, Doudna began to worry. In the dream, a colleague asked if she would help teach someone how to use CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats). She followed him into a room to be greeted by Adolph Hitler wearing a pig face. The nightmare reinforced her belief that public discussion of the technology...
Related Articles
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...